Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This study is a single-arm, open-label, single-center study to assess the safety of
tislelizumab with BCG, and to obtain the preliminary efficacy results in subjects who have
been diagnosed with high-risk NMIBC without prior BCG treatment.